Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2016/05/13 16:53:54」(JST)

wiki en

Pexelizumab is a drug designed to reduce side effects of coronary artery bypass grafting^[1] and angioplasty,^[2]^[3] among other types of cardiac surgery. It is a single chain variable fragment of a monoclonal antibody targeted against component 5 of the complement system.^[4]

Current Status

Alexion, the developer of pexelizumab stopped development due to disappointing phase 3 results indicating the heart-attack drug is no better than placebo.^[5]

References

^ ClinicalTrials.gov: Pexelizumab in Patients Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary Bypass
^ ClinicalTrials.gov: Pexelizumab in Conjunction With Angioplasty in Acute Myocardial Infarction
^ Testa, L; Van Gaal, WJ; Bhindi, R; Biondi-Zoccai, GG; Abbate, A; Agostoni, P; Porto, I; Andreotti, F; et al. (2008). "Pexelizumab in ischemic heart disease: a systematic review and meta-analysis on 15,196 patients". The Journal of thoracic and cardiovascular surgery 136 (4): 884–93. doi:10.1016/j.jtcvs.2007.12.062. PMID 18954626.
^ Mathew, JP; Shernan, SK; White, WD; Fitch, JC; Chen, JC; Bell, L; Newman, MF (2004). "Preliminary report of the effects of complement suppression with pexelizumab on neurocognitive decline after coronary artery bypass graft surgery.". Stroke; a journal of cerebral circulation 35 (10): 2335–9. doi:10.1161/01.STR.0000141938.00524.83. PMID 15331798.
^ [1] Analysis: Alexion's pexelizumab fails

This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it.

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 心臓の虚血性再潅流障害 ischemic reperfusion injury of the heart

English Journal

Relative Prognostic Value of Baseline Q Wave and Time from Symptom Onset Among Men and Women With ST-Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention.

Kaul P, Fu Y, Westerhout CM, Granger CB, Armstrong PW.SourceUniversity of Alberta, Edmonton, Alberta, Canada.
The American journal of cardiology.Am J Cardiol.2012 Aug 21. [Epub ahead of print]
Q waves have been shown to be a stronger prognostic marker than time from symptom onset to percutaneous coronary intervention (PCI) in ST-segment elevation myocardial infarction. We examined whether the relative importance of these 2 measurements is modulated by patient gender. Q waves in the area o
PMID 22920928

Pexelizumab fails to inhibit assembly of the terminal complement complex in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Insight from a substudy of the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial.

Martel C, Granger CB, Ghitescu M, Stebbins A, Fortier A, Armstrong PW, Bonnefoy A, Theroux P.SourceDepartment of Medicine, Montreal Heart Institute and University of Montreal, Montreal, Quebec, Canada.
American heart journal.Am Heart J.2012 Jul;164(1):43-51. Epub 2012 Jun 15.
BACKGROUND: Reasons for pexelizumab lack of benefit in ST-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention remain unclear. In a substudy of the APEX-AMI trial, we explored the hypothesis that early complement activation preceding drug administration expl
PMID 22795281

Japanese Journal

Preliminary report of the effects of complement suppression with pexelizumab on neurocognitive decline after coronary artery bypass graft surgery

Stroke 35, 2335-2339, 2004
NAID 30022681128

Impact on pexelizumab, an anti-C5 complement antibody, on total mortality and adverse cardiovascular outcome in cardiac surgical patients undergoing cardiopulmonary bypass

Ann Thrac Surg 77, 942-950, 2004
NAID 30008578572

Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary precutaneous coronary intervention in acute myocardial infarction

Circulation 108, 1184-1190, 2003
NAID 30022668958

Related Pictures

★リンクテーブル★

リンク元

「mab」

Pexelizumab
Monoclonal antibody
Type	Single-chain variable fragment
Source	Humanized (from mouse)
Target	Complement component 5
Legal status
Legal status	investigational;
Identifiers
ATC code	none
ChemSpider	none
UNII	CHZ6OLQ3UU
(verify)

　　[★]

関: モノクローナル抗体

mab

abciximab
adahmumab
adalimumab
afelimomab
alemtuzumab
apolizumab
arcitumomab
basiliximab
bevacizumab
cantuzumab
certolizumab
cetolizumab
cetuximab
clenoliximab
daclizumab
デノスマブ denosumab 抗RANKL抗体
eculizumab
edrecolomab
efalizumab
epratuzumab
galiximab
gemtuzumab
ibritumomab
インフリキシマブ infliximab 抗TNF-α抗体クローン病 Ph⁺ALL
inotuzumab
keliximab
natalizumab
nebacumab
omalilzumab
omalizumab
oregovomab
palivizumab
panitumumab
pertuzumab
pexelizumab
リツキシマブ rituximab：抗CD20抗体：慢性リンパ性白血病、B細胞リンパ腫

[1] ClinicalTrials.gov: Pexelizumab in Patients Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary Bypass

[2] ClinicalTrials.gov: Pexelizumab in Conjunction With Angioplasty in Acute Myocardial Infarction

[3] Testa, L; Van Gaal, WJ; Bhindi, R; Biondi-Zoccai, GG; Abbate, A; Agostoni, P; Porto, I; Andreotti, F; et al. (2008). "Pexelizumab in ischemic heart disease: a systematic review and meta-analysis on 15,196 patients". The Journal of thoracic and cardiovascular surgery 136 (4): 884–93. doi:10.1016/j.jtcvs.2007.12.062. PMID 18954626.

[4] Mathew, JP; Shernan, SK; White, WD; Fitch, JC; Chen, JC; Bell, L; Newman, MF (2004). "Preliminary report of the effects of complement suppression with pexelizumab on neurocognitive decline after coronary artery bypass graft surgery.". Stroke; a journal of cerebral circulation 35 (10): 2335–9. doi:10.1161/01.STR.0000141938.00524.83. PMID 15331798.

[5] [1] Analysis: Alexion's pexelizumab fails

匿名

検索

案内

案内

pexelizumab